Nov 09, 2022 05:35 AM

OPINION

Analysis: Will Scholz’s Visit Help BioNTech’s Covid Shot in China?

By Gao Yi and Zheng Jie

BioNTech delivered more than 2.6 billion doses to more than 165 countries and regions in 2021 and has signed orders to deliver 2.4 billion doses in 2022.

BioNTech delivered more than 2.6 billion doses to more than 165 countries and regions in 2021 and has signed orders to deliver 2.4 billion doses in 2022.

(Blue View) — Under a collaboration accord between China and Germany reached last week during German Chancellor Olaf Scholz’s visit to Beijing, BioNTech SE’s Covid-19 vaccine is to be made available to foreigners in China.

The agreement is seen as a potential first step toward offering the advanced mRNA shot more widely across the Chinese mainland. BioNTech’s China partner is Shanghai Fosun Pharmaceutical Group Co.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Innovation Takes Off at Flying Vehicle Expo

PODCAST

Caixin Deep Dive: How China’s Crypto Ban Makes Disposing of Seized Assets a Lot Harder

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s Factory Exodus Is Turning Vietnam Into the World’s Assembler

2: Meituan Enters Open-Source AI Race With LongCat Model

3: Ex-UBS Banker in Hong Kong Jailed 10 Years for Laundering $17.2 Million

4: Saudi Power Giant ACWA Bets Big on China’s Renewable Energy Market

5: End of U.S. Tax Exemption Hits Chinese Air Cargo Carriers Differently

SPONSORED

OR